Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-matched Analysis of a Large Research Network

  • Yousaf B. Hadi
    Section of Gastroenterology and Hepatology, Department of Medicine, West Virginia University, Morgantown, WV.
  • Syeda F.Z. Naqvi
    Section of Pulmonary and Critical Care Medicine, Department of Medicine, West Virginia University, Morgantown, WV.
  • Justin T. Kupec
    Section of Gastroenterology and Hepatology, Department of Medicine, West Virginia University, Morgantown, WV.
  • Sarah Sofka
    Section of Internal Medicine, Department of Medicine, West Virginia University, Morgantown, WV.
  • Arif Sarwari
    Section of Internal Medicine, Department of Medicine, West Virginia University, Morgantown, WV.

説明

<jats:sec> <jats:title>Background.</jats:title> <jats:p>Organ transplant recipients comprise an immunocompromised and vulnerable cohort. Outcomes of coronavirus disease 2019 (COVID-19) in solid organ transplant (SOT) recipients remain understudied.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods.</jats:title> <jats:p>We used a multicenter federated research network to compare clinical outcomes of COVID-19 in patients with SOT to a propensity--matched cohort of patients without SOT.</jats:p> </jats:sec> <jats:sec> <jats:title>Results.</jats:title> <jats:p>We identified 2307 SOT recipients and 231 047 nontransplant patients with COVID-19. Transplant patients were more likely to be male individuals, older, have a body mass index >30 kg/m<jats:sup>2</jats:sup>, and have comorbid hypertension, diabetes, nicotine dependence, heart failure, and ischemic heart disease compared with the nontransplant group (<jats:italic toggle="yes">P</jats:italic> < 0.05). One-to-one matching was performed for diabetes, hypertension, chronic lung diseases, race, nicotine dependence, heart failure, ischemic heart disease, and gender. There was no difference in the composite outcome of intubation or mechanical ventilation at 30 days (risk ratio [RR], 1.04; 95% confidence interval [CI], 0.86-1.26) or 60 days (RR, 1.03; 95% CI, 0.86-1.24) between the 2 groups. Hospitalization rate was higher in the transplant cohort (30.97% versus 25.47%; RR, 1.22; 95% CI, 1.11-1.34). There was no difference in mortality at 30 days (6.45% versus 5.29%; RR, 1.22; 95% CI, 0.88-1.68) or 60 days postdiagnosis (RR, 1.05; 95% CI, 0.83-1.32). More patients in the SOT group developed acute renal injury compared with non-SOT cohort (24.73% versus 14.29%; RR, 1.73; 95% CI, 1.53-1.96).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions.</jats:title> <jats:p>Patients with SOT have high COVID-19-related mortality; however, propensity-matched analyses reveal that this increased risk is secondary to higher burden of comorbidities. SOT status independently increases risk of hospital admission and acute kidney injury.</jats:p> </jats:sec>

収録刊行物

  • Transplantation

    Transplantation 105 (6), 1365-1371, 2021-02-05

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ